Human papillomavirus typing of invasive cervical cancers in Italy by Del Mistro, Annarosa et al.
BioMed  Central
Page 1 of 3
(page number not for citation purposes)
Infectious Agents and Cancer
Open Access Short report
Human papillomavirus typing of invasive cervical cancers in Italy
Annarosa Del Mistro*1, Helena Frayle Salamanca1, Rossana Trevisan1, 
Roberta Bertorelle1, Anna Parenti2, Emanuela Bonoldi3, Paola Zambon4 and 
Daria Minucci5
Address: 1Immunologia e Diagnostica Molecolare Oncologica, Istituto Oncologico Veneto, Padova, Italy, 2Anatomia Patologica, Azienda 
Ospedaliera di Padova, Padova, Italy, 3Anatomia Patologica, Ospedale di Vicenza, Vicenza, Italy, 4Registro Tumori Veneto, Istituto Oncologico 
Veneto, Padova, Italy and 5Ostetricia e Ginecologia, Azienda Ospedaliera di Padova, Padova, Italy
Email: Annarosa Del Mistro* - annarosa.delmistro@unipd.it; Helena Frayle Salamanca - helena.frayle@unipd.it; 
Rossana Trevisan - rossana.trevisan@libero.it; Roberta Bertorelle - roberta.bertorelle@unipd.it; Anna Parenti - anna.parenti@unipd.it; 
Emanuela Bonoldi - emanuelabonoldi@libero.it; Paola Zambon - paola.zambon@unipd.it; Daria Minucci - daria.minucci@unipd.it
* Corresponding author    
Abstract
Background: Human papilloma viruses (HPV) are the necessary cause of invasive cervical cancer
(ICC). Of the many different types identified so far, only a few of them account for the great
majority of cases worldwide, with geographical differences in their distribution. Data on the local
distribution are now of interest in view of the soon-to-come introduction of HPV type-specific
prophylactic vaccines.
Results: We have investigated HPV type distribution in samples of 48 ICC cases occurred in
women living in North-East Italy in the years 1997–1999. Cases were extracted from the Venetian
Tumour Registry files, as incident cases whose specimens had been processed in two Pathology
Departments. Search and typing were performed by polymerase chain reaction (PCR) using GP5+/
GP6+ primers, followed by direct sequencing or reverse dot blot. Three cases were PCR negative
using the housekeeping primers and hence excluded. One case was negative by all HPV tests used.
HPV 16 was present in 32 (72.7%) cases, as single infection in 28, in mixed infection in 4. Of the 44
positive cases, HPV 16 and HPV 18 accounted for 33 (75%), as single or mixed infections. The other
high risk HPV types accounted for 11 (25%) of the remaining infections. Of the 32 HPV 16 positive
cases, sequencing of the E6 gene could be performed in 25; the prototype isolate was identified in
7, and the variant T350G in 18; in 4 cases one or more additional mutations were present.
Conclusions: Our results suggest that HPV 16 has a very high prevalence among women with
invasive cervical cancer in Italy; therefore, the use of a prophylactic vaccine for HPV types 16 and
18 could prevent up to 75% of invasive cervical cancers in Italy.
Findings
Persistent infection with high risk HPV is a necessary cause
for invasive cervical cancer; studies on HPV type distribu-
tion among ICC cases worldwide have shown some geo-
graphical variation [1]. Limited data on HPV type
distribution among ICC cases from Italy are available to
date [2]; this information is useful in view of the availabil-
ity of type-restricted prophylactic vaccines in the very near
Published: 27 December 2006
Infectious Agents and Cancer 2006, 1:9 doi:10.1186/1750-9378-1-9
Received: 25 October 2006
Accepted: 27 December 2006
This article is available from: http://www.infectagentscancer.com/content/1/1/9
© 2006 Del Mistro et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Infectious Agents and Cancer 2006, 1:9 http://www.infectagentscancer.com/content/1/1/9
Page 2 of 3
(page number not for citation purposes)
future. We retrieved consecutive incident cases of ICC
occurred during the years 1997–1999 in Italian women
living in the North-East area from the Venetian Tumour
Registry files, and selected the cases whose samples had
been processed in the Pathology Departments of Padova
and Vicenza.
A total of 48 ICC cases were selected; 43 squamous cell
cancers (SCC) and 5 adenocarcinomas. Median age at
diagnosis was 55 yrs (range 28–89). DNA was extracted
from formalin-fixed paraffin-embedded samples by using
the QIAamp DNA minikit (Qiagen GmbH, Germany),
according to the manufacturer's instructions. To verify
DNA quality, amplification of a 268 bp fragment of the
Beta-globin gene was performed using PC04/GH20 prim-
ers. HPV detection was conducted using GP5+/GP6+ gen-
eral consensus primers (which amplify a fragment of
approximately 140–150 bp), as previously described [3],
and 0.5 U of AB SuperTaq (AB Analitica, Padova, Italy).
HPV types were identified by direct sequencing; PCR
products were purified by ExoSAP-IT (USB Corporation,
Ohio, USA) and subjected to cycle sequencing by ABI
PRISM Big Dye Terminator Cycle Sequencing kit (Applera,
Foster City, CA, USA), and sequencing reactions were run
on the ABI PRISM 310 Genetic Analyzer (Applied Biosys-
tems). The BLAST server was used to match all sequences
available in GenBank [4]. HPV 16 type specific primers
H16L1/H16R3 were used to amplify a 323 bp fragment in
the E6 gene, as previously described [5], and the frag-
ments subjected to direct sequencing (from both direc-
tions) to characterize the isolates; variants were defined by
comparison to HPV 16 prototype sequences. HPV 16 and
HPV 18 type specific primers amplifying fragments of 98
bp and 118 bp, respectively, were also used, as previously
described [6]. Samples resulted negative for HPV DNA or
untypable by direct sequencing and type-specific PCRs
were further tested by nested PCR and reverse dot blot by
using the HPV-HS BIO and HPV Strip Detection kits (AB
Analitica, Padova, Italy), according to the manufacturer's
instructions, which allow the detection of HPV types 6,
11, 34, 40, 43, 44, 53, 54, 61, 69, 70, 16, 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59, 66.
Of the 48 cases analyzed, 3 SCC resulted negative for the
housekeeping gene and were excluded, and 1 SCC was
negative for HPV DNA with all the tests used. The remain-
ing 44 cases (97.8%) were positive for HPV sequences; 39
single infections and 5 (11.4%) double infections, as
described in Table 1. In 8 cases the type could be deter-
mined only by nested PCR followed by reverse dot blot,
and all the 5 mixed infections were in this group. Overall,
the most frequently detected types were HPV 16, 18 and
33 (cumulatively, 37/44, 84.1%). HPV 16 E6 gene could
be sequenced in 25 cases; in 6 cases amplification with the
E6 type specific primers was negative, and in 1 the ampli-
fied fragment could not be successfully sequenced. The E6
pattern corresponded to the prototype in 7 cases, while
the T350G mutation was present in 18; as single mutation
in 14, with another mutation in 3 (T256C, A257G,
A442C, respectively), and with three additional muta-
tions in 1 (T286A, A289G, C335T).
Overall, 44 out of the 45 valuable ICC Italian cases
occurred during 1997–1999 were HPV positive. HPV 16
was detected in 32 cases (72.7%), a result indicating a very
high prevalence in Italy, in keeping with other studies
[2,7,8]. Indeed, in our region HPV 16 is the most preva-
lent type also in high grade lesions; 40% of samples cyto-
logically diagnosed as high grade squamous
intraepithelial lesions [9], and 65.5% (36/55) of histolog-
ically confirmed CIN3/CIS (data not shown). These data
are in line with the notion that HPV 16 positive infections
are at great risk of clinical progression and need a closer
follow-up, as recommended also by other authors [10].
This implies that when searching for HPV sequences in
clinical samples, careful attention must be paid to the
detection of type 16; in our experience, testing by HPV 16
type-specific PCR in adjunct to consensus primers PCR is
very useful to guarantee high sensitivity for this type, since
HPV 16 infections can sometimes be missed by consensus
primers in cases of mixed infections and/or low viral load.
A mixed infection was detected in 5 (11.4%) of our cases;
this result is somehow surprising, but mixed infections
have been detected in invasive cervical cancers also by
other authors [11]. Indeed, different data have been
obtained so far on the frequency and the role in cervical
neoplasia development of coinfections with multiple
HPV types. This can be due to differences in the studied
population or in the typing methodology used. In our
study the five double infections were all found by nested
PCR followed by reverse dot blot, and it is known that
Table 1: HPV type distribution in relation to histology among 44 
HPV positive invasive cervical cancers.
HPV types Histology
Squamous cell carcinoma Adenocarcinoma
HPV 16 26 2
HPV 16 + HPV 18 3
HPV 16 + HPV 31 1
HPV 18 1
HPV 33 2 2
HPV 35 1
HPV 45 2
HPV 52 1
HPV 56 + HPV 70 1
HPV 58 2Infectious Agents and Cancer 2006, 1:9 http://www.infectagentscancer.com/content/1/1/9
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reverse hybridization methods are more sensitive than
sequencing in detecting multiple genotypes [12].
Sequence analysis of the E6 gene in 25 HPV 16 positive
ICC cases showed the presence of the T350G mutation in
the great majority (18/25, 72%), in 4 cases also accompa-
nied by other mutations; among the mutations identified,
A257G, C335T, T350G, A442C lead to amino acid
changes (I52V, H78Y, L83V, E113D, respectively), while
C256T, T286A, A289G are silent not leading to amino
acid changes [13,14]. Interestingly, the A257G mutation
has been firstly described very recently, and occurred in
combination with the T350G variant [14], as in our case.
Variations in the viral genes leading to amino acid substi-
tutions can alter the biological functions of the encoded
proteins or their antigenic properties. Of the naturally
occurring HPV 16 viral variants, the T350G (L83V) is the
most commonly found among invasive cancers [15], and
has been linked to an increased risk for cervical disease
progression [14].
HPV 33 was detected in 4 cases, resulting the second most
frequent type (together with type 18), a result observed
also in The Netherlands [16].
In conclusion, our results suggest that HPV 16 has a very
high prevalence among women with invasive cervical can-
cer living in Italy, implying that a prophylactic vaccine for
types 16 and 18 could prevent up to 75% of cancer cases
in Italy.
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